Molnupiravir (MK-4482/EIDD-2801) inhibits SARS-CoV-2 replication in Syrian Hamster Model

Results:

In-vitro inhibitory effect of EIDD-1931 on SARS-CoV-2 replication in Calu-3 cells:

• EIDD-1931 treatment resulted in a decrease in SARS-CoV-2 replication by approximately 3-logs (880-fold)when compared to no drug controls.
• The IC50 value for EIDD-1931 was shown to be at sub-micromolar levels in Calu-3 cells at 414.6nM.
• Absence of toxicity - Viability was assessed over differing concentrations, demonstrating only minimal cellular toxicity at the highest drug concentration(EIDD-193140μM).

Efficacy of the MK-4482 prodrug in the Syrian hamster model:

• Virus shedding: Levels of viral RNA in the oral cavity decreased from day 2 to 4but were similar between all groups at these two-time points of analysis (~ 10⁸ and 10⁷, for days 2 and4 post-infection, respectively).
• Lung tissue samples: A 1-log decrease in viral RNA was detected in the lungs of pre-infection and post-infection groups, respectively, when compared to the vehicle control group, which corresponded to a 2-log decrease in infectious virus in the lungs of the MK-4482 treated groups when compared to the vehicle controls.
• Immunoreactivity against SARS-COV-2 antigen: Vehicle controls contained significantly more antigen than treated groups, with vehicle controls having on average 4.71 times more antigen signal than pre-infection treatment animals and 3.68 times more signal than post-infection treatment animals.
• Level of MK-4482 in lungs: All treated animals displayed detectable levels of EIDD-1931 in lung and levels were similar across treatment groups (pre-infection: 18.80 ± 5.97 nmol/g lung, post-infection 17.56 ± 5.49 nmol/g lung).
• RNA copying errors: Viral genomes from MK-4482 treated animals had a significant accumulation of nucleotide substitutions. These results are consistent with the RNA copying errors function of MK-4482 in reducing infectious virus and disease intreated animals

This study supports the potential utility of Molnupiravir to control SARS-CoV-2 infection in humans following high-risk exposure as well as for the treatment of COVID-19 patients.

                                                                                                 Take away

• Molnupiravir has an advantage of oral administration.
• Initiation of Molnupiravirwithin 12 h of a productive exposure resulting in infection significantly reduces SARS-CoV-2 replication and associated pathology in the lung target organ.